Sarepta Therapeutics (SRPT) Long-Term Investments (2013 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Long-Term Investments of $270.7 million for Q1 2026, up 148.06% year-over-year from $109.1 million in Q1 2025, and up 25730.15% quarter-over-quarter from $1.0 million in Q4 2025.
Sarepta Therapeutics (SRPT) Long-Term Investments (2013 - 2026) Analysis & Trends
Sarepta Therapeutics' Long-Term Investments history runs 14 years deep, the most recent figure standing at $270.7 million for Q1 2026.
- In Q1 2026, Long-Term Investments rose 148.06% year-over-year to $270.7 million; the TTM figure through Mar 2026 stood at $270.7 million (up 148.06% YoY), while the FY2025 annual figure was $1.0 million, down 99.21% from the prior year.
- Long-Term Investments for Q1 2026 stood at $270.7 million, up from $1.0 million in the prior quarter.
- The five-year high for Long-Term Investments was $324.1 million in Q2 2025, with the low at $1.0 million in Q4 2025.
- The 5-year median for Long-Term Investments is $31.0 million (2023), against an average of $62.6 million.
- Peak annual rise in Long-Term Investments reached 4161.11% in 2025, while the deepest fall reached 99.21% in 2025.
- Sarepta Therapeutics' Long-Term Investments stood at $31.3 million in 2022, then tumbled by 79.16% to $6.5 million in 2023, then surged by 1940.19% to $133.2 million in 2024, then plunged by 99.21% to $1.0 million in 2025, then soared by 25730.15% to $270.7 million in 2026.
- Business Quant data shows SRPT's Long-Term Investments at $270.7 million in Q1 2026, $1.0 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 362.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 362.70 Mn |
| Mar 31, 2026 | 270.70 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | 324.10 Mn |
| Mar 31, 2025 | 109.13 Mn |
| Dec 31, 2024 | 133.16 Mn |
| Sep 30, 2024 | 4.72 Mn |
| Jun 30, 2024 | 7.61 Mn |
| Mar 31, 2024 | 33.92 Mn |
| Dec 31, 2023 | 6.53 Mn |
| Sep 30, 2023 | 7.50 Mn |
| Jun 30, 2023 | 19.02 Mn |
| Mar 31, 2023 | 31.00 Mn |
| Dec 31, 2022 | 31.32 Mn |
| Sep 30, 2022 | 33.24 Mn |
| Jun 30, 2022 | 33.23 Mn |
| Mar 31, 2022 | 9.65 Mn |
| Dec 31, 2021 | 34.89 Mn |
| Sep 30, 2021 | 9.30 Mn |